Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05502250 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission

Study acronym: HOVON164HL
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Apr 2027 to Mar 2028 Trial status: Recruiting to Active, Not Recruiting · Completion date: Apr 2030 to Mar 2031 · Site details revised at 15 of 15 sitesv6 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Apr 2030 to Mar 2031
    • Site details revised at 15 of 15 sites
  2. Site details revised at 14 of 15 sitesv5
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 2023 to Jul 14, 2023 · Site details revised at 15 of 15 sitesv4 Show 2 more changesShow less
    • Start date changed from estimate of Apr 2023 to Jul 14, 2023
    • Site details revised at 15 of 15 sites
  4. Start date: Jan 2023 to Apr 2023 Primary completion date: Jan 2027 to Apr 2027 · Completion date: Jan 2030 to Apr 2030v3 Show 2 more changesShow less
    • Primary completion date: Jan 2027 to Apr 2027
    • Completion date: Jan 2030 to Apr 2030
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial investigates the efficacy and safety of the drug tislelizumab in combination with chemotherapy as a treatment for patients with R/R HL. Tislelizumab is given in combination with chemotherapy (gemcitabine and cisplatin) followed by consolidation with tislelizumab alone. The study primary question is whether this strategy works as well as the standard treatment with intensive chemotherapy and autologous stem cell transplant.
Trial Details
NCT Number NCT05502250
Lead Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland
Collaborators: Danish Lymphoma Group
Conditions Hodgkin Lymphoma
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov